Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Moderna’s SEC disclosures can feel like reviewing lab notes written in legal code. Each 10-K or 10-Q hides critical details on mRNA platform costs, clinical trial readouts, and vaccine royalty streams—information investors need but rarely have time to decode. That’s why we built a page focused on Moderna SEC filings explained simply.
Our AI engine reviews every document the moment it hits EDGAR, then delivers plain-language takeaways. Whether you’re tracking Moderna quarterly earnings report 10-Q filing for fresh revenue guidance or monitoring Moderna insider trading Form 4 transactions before the next data release, you’ll see what moved, why it matters, and where in the filing the story lives.
- Real-time alerts on Moderna Form 4 insider transactions so you never miss executive stock moves.
- Concise breakdowns of 8-K material events—yes, “Moderna 8-K material events explained” is exactly what we do.
- Moderna annual report 10-K simplified: R&D spend, BARDA contract terms, patent litigation—all summarized.
- Side-by-side charts for Moderna earnings report filing analysis to compare quarter-over-quarter vaccine demand.
Need the proxy? Our coverage connects Moderna proxy statement executive compensation to performance metrics so you can assess alignment. Curious about insider sentiment? We surface Moderna executive stock transactions Form 4 in a single click. And if you’re just understanding Moderna SEC documents with AI for the first time, our contextual footnotes show the accounting rules behind each disclosure.
Stop digging through PDFs. Start making informed decisions with AI-powered summaries, intuitive filters, and instant updates across every Moderna filing type.
Insider transactions by Moderna CFO James M. Mock: The filing reports restricted stock unit (RSU) activity for James M. Mock on 08/27/2025 and 08/28/2025. On 08/27/2025, 774 RSUs were converted into 774 shares of common stock and 375 shares were withheld to satisfy tax withholding, leaving 17,340 shares beneficially owned after the reported sale or disposition. On 08/28/2025, 329 RSUs converted into 329 shares and 160 shares were withheld for taxes, leaving 17,509 shares beneficially owned. Vesting schedules for the awards are disclosed and tax-withholding elections are noted.
Reporting person: Shannon Thyme Klinger, Chief Legal Officer of Moderna, reported equity transactions in the issuer's common stock. The filing shows conversion of restricted stock units (RSUs) into common shares and contemporaneous share withholdings to satisfy tax obligations. Specifically, 774 RSUs converted into 774 shares on 08/27/2025 and 329 RSUs converted into 329 shares on 08/28/2025. On 08/27/2025 the reporting person had 28,257 shares after a 774-share conversion and a 375-share withholding; on 08/28/2025 the filing shows 28,051 shares after a 329-share conversion and a 160-share withholding. The RSU awards vest 25% at the initial vesting date with the remainder in twelve equal quarterly installments.
Stephen Hoge, President and director of Moderna, Inc. (MRNA), reported Section 16 transactions showing conversion of restricted stock units into common stock and related share withholding for taxes. On 08/27/2025, 1,437 RSUs converted into common stock and 695 shares were withheld at $24.73 to satisfy tax obligations, leaving 1,453,556 shares beneficially owned after that transaction. On 08/28/2025, 611 RSUs converted and 296 shares were withheld at $25.10, with total owned shares reported at 1,453,176. The report also discloses 4,116 shares held indirectly by Valhalla, LLC and 151,933 shares owned by a trust for the benefit of the reporting person’s spouse and children, of which the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Filing: Form 4 filed for Moderna, Inc. (MRNA) reporting the vesting and conversion of restricted stock units into common stock by Director David M. Rubenstein.
Key facts: On 08/05/2025 850 restricted stock units vested and converted one-for-one into 850 shares of common stock at a price of $0. Following the transaction, the reporting person beneficially owned 1,527 shares. The Form 4 was signed by attorney-in-fact James Dillon on 08/06/2025. The filing indicates a direct ownership form and uses transaction code M with no other transactions disclosed.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
